<DOC>
	<DOCNO>NCT01010724</DOCNO>
	<brief_summary>The study drug bIAP , match placebo , administer bolus 1000 Units bIAP match placebo prior anaesthesia ( T = -15 minute ) , directly follow intravenous continuous infusion 5.6 unit per kg bodyweight/hr pump rate 4 ml/hr approximately 36 hr ( total 200 IU/kg/36 hr ) total 50 patient schedule coronary artery bypass graft surgery ( CABG ) . Risk surgical complication mortality due co-morbid condition collect EuroSCORE use screen patient prior surgery .</brief_summary>
	<brief_title>Efficacy Safety Study bIAP</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Male nonpregnant , nonlactating female patient race age &gt; 18 year . Women must nonchildbearing potential . 2 . Patients schedule coronary artery bypass surgery CPB . 3 . Patients must EuroSCORE ( Appendix I ) &gt; 2 &lt; 6 . 4 . Patients give write informed consent prior participation trial undertake comply protocol . 1 . Patients unwilling unable fully evaluate followup . 2 . Patients undergo CABG emergency due complication percutaneous transluminal coronary angioplasty ( PTCA ) / catheterization , unstable angina ongoing myocardial infarction . 3 . Patients base alkaline phosphatase level &gt; 100 IU/l ( 70 IU/L mean concentration ) level , level &lt; 30 IUnits/L ( ammediol , DEA unit ) ( values base level glycine unit pH9.6 25 C respectively &gt; 40 &lt; 12 IU/L ) . 4 . Patients show preoperative infection suspect endocarditis systemic infection . 5 . Patients refuse accept medicallyindicated blood product . 6 . Patients evidence significant hepatic disease , include history clinical sign laboratory value total bilirubin &gt; 2.0 mg/dL , ALT AST &gt; 3X upper limit normal . 7 . Patients receive investigational drug 30 day prior study drug administration , currently participate study administration investigational drug within one month anticipate . 8 . Patients require preoperative ventilatory support . 9 . Patients renal insufficiency ( history creatinine &gt; 2.0 mg/dL ) chronic renal failure require dialysis . 10 . Patients plan receive leukocytedepletion filtration part bypass circuitry . 11 . Patients severe neurological deficit ( see Appendix I ) . 12 . Patients recent history substance alcohol abuse . 13 . Patients diagnosis idiopathic thrombocytopenia . 14 . Concomitant surgical procedure ( i.e. , include Appendix VI ) anticipate require great 2.5 hour time `` onpump '' patient surgery coronary artery bypass surgery plan 30day study period . 15 . Patients history cancer receive chemotherapy radiation therapy within past 3 month . Patients receive adjuvant hormonal therapy exclude . If cancer resolve completely , patient enrol without permission Alloksys . 16 . Patients schedule receive `` stress dos '' glucocorticoid ( i.e. , dose &gt; 2 mg/kg/day methylprednisolone equivalent ) prior , follow operation . 17 . Patients vegetarians vegenists patient may expect tolerant bovine protein . 18 . Patients BMI ( body mass index ) &lt; 18 &gt; 30 19 . Patients , opinion Investigator Sponsor , unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>